ATE452648T1 - Gonadotropin releasing hormone antagonist in gel- formenden konzentrationen - Google Patents

Gonadotropin releasing hormone antagonist in gel- formenden konzentrationen

Info

Publication number
ATE452648T1
ATE452648T1 AT02749000T AT02749000T ATE452648T1 AT E452648 T1 ATE452648 T1 AT E452648T1 AT 02749000 T AT02749000 T AT 02749000T AT 02749000 T AT02749000 T AT 02749000T AT E452648 T1 ATE452648 T1 AT E452648T1
Authority
AT
Austria
Prior art keywords
gel
gonadotropin releasing
releasing hormones
forming concentrations
antagonist
Prior art date
Application number
AT02749000T
Other languages
English (en)
Inventor
Martin Lueck
Pierre Broqua
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Application granted granted Critical
Publication of ATE452648T1 publication Critical patent/ATE452648T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT02749000T 2001-07-12 2002-07-08 Gonadotropin releasing hormone antagonist in gel- formenden konzentrationen ATE452648T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0117057.0A GB0117057D0 (en) 2001-07-12 2001-07-12 Pharmaceutical composition
PCT/GB2002/003116 WO2003006049A1 (en) 2001-07-12 2002-07-08 Gonadotropin releasing hormone antagonists in gel-forming concentrations

Publications (1)

Publication Number Publication Date
ATE452648T1 true ATE452648T1 (de) 2010-01-15

Family

ID=9918396

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02749000T ATE452648T1 (de) 2001-07-12 2002-07-08 Gonadotropin releasing hormone antagonist in gel- formenden konzentrationen

Country Status (13)

Country Link
US (4) US20050245455A1 (de)
EP (1) EP1404357B1 (de)
JP (1) JP4845166B2 (de)
AR (1) AR036337A1 (de)
AT (1) ATE452648T1 (de)
DE (1) DE60234831D1 (de)
DK (1) DK1404357T3 (de)
ES (1) ES2338217T3 (de)
GB (1) GB0117057D0 (de)
MY (1) MY139203A (de)
PT (1) PT1404357E (de)
UY (1) UY27378A1 (de)
WO (1) WO2003006049A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
KR100633280B1 (ko) 2002-09-27 2006-10-16 젠타리스 게엠베하 약제학적 활성 펩티드의 서방형 투여 형태 및 이의 제조 방법
ES2555681T3 (es) 2003-10-03 2016-01-07 Thorn Bioscience, Llc Procedimiento para la sincronización de la ovulación para la fecundación programada sin detección del celo
GB0511269D0 (en) 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
CA2671925A1 (en) * 2006-12-21 2008-07-10 Stryker Corporation Sustained-release formulations comprising crystals, macromolecular gels, and particulate suspensions of biologic agents
JOP20090061B1 (ar) 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
EP2421545B1 (de) 2009-04-23 2017-12-06 JBS United Animal Health II LLC Verfahren und vorrichtung zur synchronisierung der befruchtungszeit
JO3550B1 (ar) * 2009-05-01 2020-07-05 Ferring Int Center Sa مركب لمعالجة سرطان البروستاتا
AU2010243273B2 (en) * 2009-05-01 2016-06-16 Ferring B.V. Composition for the treatment of prostate cancer
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
EP2447276A1 (de) 2010-10-27 2012-05-02 Ferring B.V. Verfahren zur Herstellung von Degarelix und seinen Zwischenprodukten
PT2632934T (pt) 2010-10-27 2017-01-06 Ferring Bv Processo para o fabrico de degarelix e seus intermediários
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
WO2013104745A1 (en) * 2012-01-13 2013-07-18 Ferring Bv Pharmaceutical composition
KR102140982B1 (ko) 2012-06-01 2020-08-05 훼링 비.브이. 데가렐릭스의 제조 방법
ITMI20121638A1 (it) * 2012-10-02 2014-04-03 Marco Sbracia Utilizzo di degarelix nel trattamento dell'endometriosi e di patologie ad essa correlate
ES2808409T3 (es) 2012-11-28 2021-02-26 United Ah Ii Llc Método para sincronizar el tiempo de inseminación en cerdas primerizas
US10681261B2 (en) * 2012-11-30 2020-06-09 3I Avi, Llc Inspection system
TW201625218A (zh) * 2014-04-18 2016-07-16 Ｊｂｓ聯合動物保健有限責任公司 製造含ｇｎｒｈ凝膠之方法
BR112019014192A2 (pt) * 2017-01-30 2020-02-11 Antev Limited Composição compreendendo pelo menos um antagonista de gnrh
WO2019110688A1 (en) 2017-12-05 2019-06-13 Ferring B.V. A composition comprising degarelix for use in the treatment of breast cancer
EP3560555A1 (de) * 2018-04-26 2019-10-30 LifeArc Zusammensetzung zur behandlung einer oder mehrerer östrogenvermittelter krankheiten

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US200486A (en) * 1878-02-19 Improvement in apparatus for attaching harness to the shafts
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE593491T1 (de) * 1991-04-25 1994-11-17 Romano S.-Cergue Deghenghi LHRH-Antagonisten.
SI9300468A (en) * 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
US5506207A (en) * 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5860957A (en) * 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
US5821230A (en) * 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
FR2776520B1 (fr) * 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
US20020103131A1 (en) * 2001-01-26 2002-08-01 Jacobson Jill D. Prevention of diabetes by administration of GnRH antagonists
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
AR042815A1 (es) * 2002-12-26 2005-07-06 Alza Corp Dispositivo de suministro de agente activo que tiene miembros compuestos
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
EP1891964A1 (de) * 2006-08-08 2008-02-27 AEterna Zentaris GmbH Anwendung von Anfangsdosen von LHRH-Analogen und Erhaltungsdosen von LHRH-Antagonisten zur Behandlung von hormonabhängigen Krebsarten und entsprechende Kits
WO2009102720A1 (en) * 2008-02-11 2009-08-20 Safety Syringes, Inc. Reconstitution means for safety device
JOP20090061B1 (ar) * 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
AU2010243273B2 (en) * 2009-05-01 2016-06-16 Ferring B.V. Composition for the treatment of prostate cancer
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
PT2632934T (pt) * 2010-10-27 2017-01-06 Ferring Bv Processo para o fabrico de degarelix e seus intermediários
EP2447276A1 (de) * 2010-10-27 2012-05-02 Ferring B.V. Verfahren zur Herstellung von Degarelix und seinen Zwischenprodukten
JO3755B1 (ar) * 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
CA2841751A1 (en) * 2011-07-15 2013-01-24 Raymond E. Joseph Method for timing a colonoscopy wherein a picosulate composition is administered

Also Published As

Publication number Publication date
DE60234831D1 (de) 2010-02-04
ES2338217T3 (es) 2010-05-05
GB0117057D0 (en) 2001-09-05
US20040038903A1 (en) 2004-02-26
MY139203A (en) 2009-08-28
EP1404357A1 (de) 2004-04-07
PT1404357E (pt) 2010-03-16
US20110053846A1 (en) 2011-03-03
UY27378A1 (es) 2003-02-28
JP2005511491A (ja) 2005-04-28
EP1404357B1 (de) 2009-12-23
US20090018085A1 (en) 2009-01-15
JP4845166B2 (ja) 2011-12-28
US20050245455A1 (en) 2005-11-03
WO2003006049A1 (en) 2003-01-23
DK1404357T3 (da) 2010-05-03
AR036337A1 (es) 2004-09-01

Similar Documents

Publication Publication Date Title
ATE452648T1 (de) Gonadotropin releasing hormone antagonist in gel- formenden konzentrationen
EE200200400A (et) Kortikotropiini vabastava faktori antagonistid
NL301115I2 (nl) Drospirenon in combinatie met estetrol
IS6516A (is) Malónamsýrur og afleiður af þeim sem skjaldkirtilsviðtakabindlar
EE05350B1 (et) Antiproliferatiivsete vahenditena kasutatavad bensoimidasooli derivaadid
DE10085381T1 (de) Lötpasten-Kontrollsystem
IS6054A (is) Oxamsýrur og afleiður sem skjaldkirtilsviðtakabindlar
DE60231726D1 (de) Doppelkolben-einphasen-probeentnahmemechanismus und -verfahren
DE60106839D1 (de) Elektronisches Gerät mit zusammenklappbarer Anzeigevorrichtung
NO20042182L (no) Kjemisk-modifiserte veksthormonkonjugater
DE60313044D1 (de) Mehrachsige Schleifenantenne in Chip-Form
DE50102799D1 (de) Beleuchtungs- und anzeigevorrichtung
FI991140A7 (fi) Valaiseva elektroninen laite ja valaisumenetelmä
DE60118284D1 (de) Lumineszente Vorrichtung, Bildanzeigevorrichtung und Metallkoordinationsverbindung
IS7111A (is) Lyfjablanda sem felur í sér róteindadæluhemil og sýrubindandi efni
FI20000480A0 (fi) Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina
EP1361872A4 (de) Neue lysophosphatsäurerezeptor-agonisten und -antagonisten
IS7672A (is) Bóluefni gegn öldrunar- og æxlunarkerfa sýkingum í nautgripum
FI20000697A0 (fi) Menetelmä sijainnin määrityksen suorittamiseksi ja elektroniikkalaite
ITMI20031127A0 (it) Anticorpi anti-hgf e loro uso
FI20002644L (fi) Liitäntäalusta
DE60226425D1 (de) Lösliches rage-protein
IS6582A (is) Mótunarpeptíð fyrir blóðkökkmyndunarviðtaka
ATE322161T1 (de) Stoffabgabevorrichtung
DE60124627D1 (de) Phosphor-Mehrschicht und elektrolumineszente Vorrichtung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1404357

Country of ref document: EP